DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wwqd8x/the_overview_of) has announced the addition of the "The Overview of Japanese CSO Market" report to their offering.
This report explains about the CSO market situation in Japan. The readers will be able to understand overall market trend, as well as detailed information such as major CSO players, the reason why there are so many MR in Japan, and the future outlook.
When we look at the most updated data, the number of MR in 2013 increased by 3% to 65,752. Generic and CSO companies drove this growth, while new drug companies in-creased by just 1.3%. Especially, CSO has shown significant growth, by 25%. Although CSO currently accounts for only 6% share of the total, it has grown by 20%+ over the last several years. The Japan Contract Sales Organization Association (JCSOA) estimates that by 2015, CSO will account for eight to ten percent of the total.
Japanese companies normally prefer to use internal resources. Initially, non Japanese pharma started to use contract MR. Since then, it has gradually widespread to Japanese large sized pharma, and now we can also see increasing Contract MR even in small and mid sized companies. CSO business has been gaining presence over time.
While companies still hesitate to decrease the total number of sales force, they will also see the difficulty to pool large sized of internal resources. As a result, firms will likely bridge this gap by utilizing temporary staff and contract MR. The shift towards contract MR continues, primarily at foreign firms, but Japanese pharmaceutical manufacturers will also follow. Therefore, we expect CSO market will continue to expand for a while.
Without having enough block busters in the market, many of firms will face the operational challenge soon, and they will have to see downsizing the organizations. On the other hand, new entrants will be able to enjoy the market entry with fairly light internal resources, as long as they have products to be launched in Japan. That would be really one of the rare game changing times to pharmaceutical companies, and how a company cope with this opportunity will shape its organization's future.
We recommend pharma, especially new entrants, utilize contract MRs, with the support from CSO companies, knowing it is rather risky to hold internal sales force nowadays.
Key Topics Covered:
- Scope Discussed
- Medical Representative
- Number of MR
- Number of MR by Company
- Industry body
- CSO Market Size
- Related Regulation
- Major CSO Companies
- Increasing Contract MR
- Why So Many MR in Japan?
- Curbing Extreme Sales Tactics
- Business & HR Strategy at Foreign Firms in Japan
- Declining MR's Presence
- Future Outlook
- Cimic Ashfield
- EP PharmaLine
- M3 marketing
For more information visit http://www.researchandmarkets.com/research/wwqd8x/the_overview_of